CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 443 filers reported holding CRISPR THERAPEUTICS AG in Q4 2021. The put-call ratio across all filers is 1.13 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,044,829 | -28.9% | 287,394 | -12.0% | 0.02% | -20.7% |
| Q2 2023 | $18,340,852 | +31.3% | 326,698 | +5.8% | 0.03% | +26.1% |
| Q1 2023 | $13,968,561 | +32.2% | 308,834 | +18.8% | 0.02% | +27.8% |
| Q4 2022 | $10,563,389 | -39.9% | 259,862 | -3.4% | 0.02% | -41.9% |
| Q3 2022 | $17,577,000 | +5.7% | 268,992 | -1.7% | 0.03% | +10.7% |
| Q2 2022 | $16,636,000 | -51.9% | 273,783 | -50.4% | 0.03% | -36.4% |
| Q1 2022 | $34,621,000 | +59.4% | 551,564 | +92.5% | 0.04% | +83.3% |
| Q4 2021 | $21,717,000 | – | 286,595 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |